Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06946524 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT06946524 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 59 participants.
The verdict
NCT06946524, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.
Interventions
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2025-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06946524
The ClinicalTrials.gov registry entry for NCT06946524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risankizumab is the first listed.
NCT06946524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06946524 about?
NCT06946524 is a clinical study titled "A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants". This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.
What is the current status of trial NCT06946524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2025-05-08. Estimated completion is 2025-11-25.
What interventions are being tested in trial NCT06946524?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06946524?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.